Moderna (MRNA) Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SPY
3. SKA-B
4. PBA
5. ALAR
6. CCH:LN
7. META
8. CCHGY
9. PRY:IM
10. PRYMY

Go back to Moderna (MRNA) Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age

Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age

October 25, 2021 8:30 AM EDT

Results are the first from pivotal study in children aged six years to under 12 years

Two 50 g doses of mRNA-1273 were generally well tolerated and showed robust neutralizing antibody titers; primary immunogenicity endpoints were met

Moderna plans to submit results to the U.S. FDA, EMA and regulatory agencies around the world... More